Hemostemix led last week’s top performers with a 50% gain Hemostemix led last week’s top performers with a 50% gain. As highlighted last week, HEM is actively pursuing a $4M equity financing.
The company is making significant strides with ACP-01, its flagship product aimed at helping patients in critical need on a compassionate basis.
Hemostemix is initially focusing on patients with critical limb ischemia (CLI) and ischemic heart disease, two markets where there is a substantial demand for innovative treatments.
With financing efforts underway, the potential for scaling up production is on the horizon.